To our surprise, although recipients of WT AML showed high whole BM leukemic burden as anticipated from our previous studies (Barbier et al., 2020) (396.3 ± 68.26 million AML blasts), there were six-fold less BM AML blasts in recipients of Selplg–/– AML (69.3 ± 14.07 million AML blasts) (p < 0.0001, Figure 4E). This evidence concerns the gene SELPLG and acute myeloid leukemia.